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Abstract
Q fever, caused by Coxiella burnetii, may cause vascular complications, but the role that this infection may play in the development of
atherosclerotic cardiovascular disease remains unknown. This study examined the association between Q fever serology and cardiovascular
disease in a region where Q fever is endemic. A case-control study was conducted in the Hospital Universitario de Burgos (Spain) between
February 2011 and June 2012. A total of 513 samples were tested, from 454 hospitalized patients ≥65 years old, of whom 164 were cases
(patients with prevalent or incident coronary heart, cerebrovascular or peripheral artery, disease) and 290 controls (patients without
cardiovascular disease). Serum IgG antibody phase II titres against Q fever were determined by immunoﬂuorescence assay. Seropositivity
(titres ≥1:256) was detected in 84/164 (51.2%) cases and in 109/290 (37.6%) controls (p = 0.005; OR, 1.7; 95% CI, 1.1–2.5). This ratio
increases when adjusted for sex, hypertension, dyslipidaemia, smoking, diabetes and atrial ﬁbrillation (OR, 2.6; 95% CI, 1.5–4.7). The
geometric mean titre (GMT) for C. burnetii phase II assay was higher in cases than in controls (p = 0.004). We found no signiﬁcant
relationship between cardiovascular disease and C. pneumoniae, and Cytomegalovirus seropositivity (both determined by the IgG ELISA
method). In conclusion, serological evidence of past Q fever is associated with atherosclerotic cardiovascular disease in elderly patients in an
endemic region.
Keywords: Atherosclerotic disease, cardiovascular disease, Coxiella burnetii, Q fever, Q fever serology
Original Submission: 27 September 2013; Revised Submission: 20 December 2013; Accepted: 13 January 2014
Editor D. Raoult
Article published online: 20 January 2014
Clin Microbiol Infect 2014; 20: 873–878
10.1111/1469-0691.12541
Corresponding author: S. Gonzalez-Quijada, Seccion de Medicina
Interna, Bloque B, 6ª planta, Hospital Universitario de Burgos, Burgos,
Spain
E-mail: santiago-monica@hotmail.com
Introduction
Coxiella burnetii is a strict intracellular pathogen causing Q
fever, a worldwide zoonosis with an extensive animal reservoir
[1–3]. Infected animals suffer from spontaneous abortions and
other obstetric complications. In humans, it can cause a
self-limited ﬂu-like illness, pneumonia and hepatitis, but a large
proportion of cases are asymptomatic [1–3]. Chronic Q
fever infections are frequently associated with cardiovascular
complications [4], mainly endocarditis [3], and also aortic
aneurysms and vascular-graft infection [4,5]. Serology is the
cornerstone of diagnosis, and immunoﬂuorescence assay is the
current reference method for the serodiagnosis of Q fever [1].
Persistent infection may contribute to the pathogenesis of
atherosclerosis. Chlamydia pneumonia and Cytomegalovirus
(CMV) are possibly the microorganisms most studied, but
many others may be involved [6]. Coxiella burnetii is a plausible
candidate, because in addition to the above, it can cause
myocardial infarction [7], myocarditis [1], stroke [4], and
thrombus and arterial embolism [8]. As regards these data,
some authors have investigated whether there is an associa-
tion between past infection due to C. burnetii and cardiovas-
cular disease in middle-aged subjects. However, the results so
far have been controversial [9–13]. This relationship has never
been studied in the elderly population, in whom the prevalence
of both diseases (cardiovascular disease and Q fever) is higher
than in middle-aged subjects. The latter is especially evident in
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endemic areas of Europe, where seroprevalence in the elderly
can reach 70% [14].
To clarify this issue, the association between Q fever
serology and cardiovascular disease was analysed in elderly
patients in a highly endemic region.
Methods
Patients and sample selection criteria
A case-control study was conducted in the Hospital Univer-
sitario de Burgos (Burgos area, Spain) between February 2011
and June 2012. This centre is the only public hospital in its area,
which covers around 200 000 inhabitants. A total of 513
samples were tested, from 454 hospitalized patients ≥65 years
old, of whom 164 were cases and 290 controls. The study
protocol was reviewed and approved by the Clinical Research
Ethics Committee of this hospital, and the patients signed an
Informed Consent Form (adapted to the Declaration of
Helsinki principles).
The cases were those who had prevalent or incident
atherosclerosis cardiovascular disease, deﬁned as coronary
heart disease, manifested by myocardial infarction or angina
pectoris, and/or cerebrovascular disease, manifested by stroke
and transient ischaemic attack, and/or peripheral artery
disease, manifested by intermittent claudication to limb-threat-
ening ischaemia [15]. Heart failure and brain haemorrhage
were not included in the deﬁnition of the case group. The
presence of atrial ﬁbrillation, or other known source of cardiac
emboli (valvular prosthesis, valvulopaties), was not cause of
exclusion from the case group. This is because the presence of
a known source of cardiac emboli does not always mean that
there is a causal relationship [16]. Indeed, thromboembolism
of aortic or large vessels atheroma should be considered in
these patients [16]. Cardiovascular disease caused by endo-
carditis, intracardiac tumors, hypercoagulable state, vasculiti-
des and other non-atherosclerotic diseases, was included in
the control group. The controls showed no history or clinical
evidence of atherosclerotic cardiovascular disease. The sample
was recruited at a rate of approximately two patients per day,
randomly selected using a computer program.
Data collection and cardiovascular risk factors
Only the histories that could be veriﬁed from a medical report
or during hospitalization were taken into account. Athero-
sclerotic cardiovascular disease was only considered valid if it
was supported by imaging techniques or, if these were not
available, was veriﬁed by a cardiovascular specialist. None of
the physicians who classiﬁed the patients knew the serological
results beforehand. Furthermore, our laboratory was not
aware of the source of the samples, nor did it have any clinical
information about them.
The control variables used were age, sex, hypertension,
diabetes, dyslipidaemia, atrial ﬁbrillation/atrial ﬂutter (sustained
or paroxysmal) and smoking. It is unknown whether the
association at issue may be inﬂuenced by any of these variables,
so we decided not to match cases and controls for any of
them. A smoker was someone who was known to have
smoked continuously (several years) at any time in their life.
We did not formulate any other deﬁnition due to the difﬁculty
of obtaining more precise information. Serum C- reactive
protein was determined, as an acute or chronic inﬂammation
may result in endothelial dysfunction, and may be responsible
for a cardiac event [17]. The co-morbidities were standardized
according to the Charlson criteria [18].
Serological determinations
Q fever serology was determined by immunoﬂuorescence assay
using reagents and test protocols from Focus Technologies
(formerly MRL, Cypress, CA, USA). Blood samples were
collected by venepuncture, and serum samples were stored at
20°C until analysis. IgG phase II titres equal to or >1:256, were
considered positive. Low titres of IgG phase II usually indicate a
past infection, but with high titres, an acute infection cannot be
ruled out [1–3]. The decision to extend the serology study (IgM
antibodies), or to rule out an acute or chronic infection, was
based on clinical criteria, and was the responsibility of an
experienced internal medicine physician. The geometric mean
titre (GMT) was also calculated in order to evaluate the
seropositivity rate. An IgG phase II titre <1:256 was assigned a
value of 1:64. To check the serological test precision, a second
serological determination was performed 2–3 days after the
ﬁrst one in 41 patients. The agreement of the resultswas 100% as
regards seropositivity, and 97.5% agreement for titres.
The same blood sample was used to determine the presence
of IgG antibody to Chlamydia pneumoniae and CMV (using
commercial enzyme-linked immunosorbent assay (ELISA) kits),
C-reactive protein (CRP), albumin and lipid proﬁle (total
cholesterol, LDL and HDL cholesterol, and triglycerides), as
well as other biochemistry and haematology parameters. An
index >0.9 for C. pneumoniae and >70 for CMV was considered
positive. The comparison of indices (Mann–WhitneyU-test) was
performed, assigning a value of 0.5 for C. pneumoniae negative
values, and a value of ‘0’ for CMV negative values.
Determination of sample size and statistical analysis
Given the prevalence of Q fever in regions adjacent to ours
[14], and expecting to see an odds ratio (OR) of 2.5 or more,
with an a risk of 5% and b of 10% (90% power of the study),
and a two-tailed hypothesis, the minimum number of cases to
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study should be 112. Logistic regression analysis was used to
test for a possible relationship between seropositivity to
Coxiella burnetti and cardiovascular disease. The data were
analysed using the statistics program, SPSS 15.0 (SPSS, Chicago,
Illinois, USA). The OR was calculated with a conﬁdence
interval of 95%. The statistical tests were considered signiﬁcant
for values of p < 0.05.
Results
Serum was available for serology in all patients. Two patients
with a history of transient ischaemic attack were included in
the control group after being unable to verify with certainty
these diagnoses. We have not found cardiovascular disease
caused by endocarditis, hypercoagulable state, vasculitides or
other non-atherosclerotic diseases. The epidemiological and
clinical characteristics of the cases and the controls are
summarized in Table 1. Except for diabetes, the rest of the
cardiovascular risk factors behaved as expected. Both groups
were similar in terms of major causes of admission and
co-morbidities. There were only 15 (9.1%) incident cases of
cardiovascular disease, of which 52.2% were seropositive.
Seropositive results were found in 53.8% of the 78 patients
who suffered from cerebrovascular disease, 50.0% of the 83
with ischaemic heart disease, 52.3% of the 44 with peripheral
arterial disease, and in 51.0% of the 41 with mixed cardiovas-
cular disease.
Unlike what happens for Coxiella (Table 2), no signiﬁcant
differences were found in the geometric mean values
obtained for Chlamydia (1.20 (range, 0.5 to 3.3), and 1.20
(range, 0.5 to 4.7); p 0.13) and CMV (53.0 (range, 0 to 400),
and 56.0 (range, 0 to 270); p 0.13) in cases and controls. A
study was conducted to rule out Q fever endocarditis in
two patients with compatible serology and refractory heart
failure. Trans-thoracic and trans-oesophageal ultrasound, as
well as the PCR assays in blood, were negative in both
cases. Twelve patients had acute respiratory infection of
atypical characteristics, but none of them had positive IgM
antibodies, and all had satisfactory outcomes with
conventional therapy.
The distribution of cardiovascular risk factors, co-morbidity
and cardiovascular diseases according to the results of
serology is shown in Table 3. Only cerebrovascular disease
is associated with seropositivity. The unadjusted and adjusted
relationships between Q fever seropositivity, Chlamydia and
CMV seropositivity, and case-control status, are shown in
Table 4. Neither the CRP nor age was included in the
regression analysis. The ﬁrst due to being similar in both
groups and second because it is a variable subject to control.
The odds of Q fever seropositivity were elevated, and
increased after adjusting for covariates and signiﬁcant interac-
tions between covariates and the main variable being studied
(Table 4). Except for hypertension, which produced a negative
interaction, the rest of the control variables were involved in
positive interactions. However, only the signiﬁcant interactions
were included in the regression model (p < 0.05). Also, none
of the cardiovascular risk factors acted as a confounding factor
when considering them individually. No interactions were
found for Chlamydia and CMV seropositivity (Table 4),
TABLE 1. Characteristics of cases and controls
Cases
(n = 164)
Controls
(n = 290) p value
Age 81.3 (7.6) 80.7 (7.7) 0.45
Men 114 (69.5) 129 (44.5) <0.001
Caucasian ethnicity 163 (99.3) 288 (99.3) 1.00
Diabetes 55 (33.5) 83 (28.6) 0.55
Hypertension 131 (79.9) 189 (65.2) 0.001
Dyslipidaemia 87 (53.0) 106 (36.6) 0.001
Atrial ﬁbrillation 85 (51.8) 103 (35.5) 0.001
Smoking 84 (51.2) 94 (32.4) <0.001
Ex-smoker 78 (47.6) 84 (29.0) <0.001
Current smoker 4 (2.4) 9 (3.1) 0.76
C-reactive protein (mg/L) 53.7 (72.3) 57.2 (71.2) 0.66
Albumin (mg/dL) 2871.4 (612.1) 2839.1 (632.6) 0.54
Other co-morbiditiesa
Congestive heart failure 57 (34.8) 80 (27.6) 0.11
Neoplasm (any) b 38 (32.2) 71 (24.5) 0.81
Chronic pulmonary disease 52 (31.7) 70 (24.1) 0.09
Dementia 23 (14.0) 45 (15.5) 0.78
Moderate or severe
renal disease
7 (4.3) 7 (2.4) 0.27
Liver disease 4 (2.4) 12 (4.1) 0.32
Connective tissue disease 3 (1.8) 8 (2.8) 0.75
Causes of hospitalization
Respiratory diseases 46 (28.0) 79 (27.2) 0.95
Gastrointestinal diseases 28 (17.1) 67 (23.1) 0.15
Other cardiovascular diseases 23 (14.0) 44 (15.1) 0.87
Urological diseases 14 (8.5) 28 (29.7) 0.73
Locomotor diseases 12 (7.3) 34 (11.7) 0.14
Haematological disease 4 (2.4) 8 (2.8) 0.55
Skin or soft tissue diseases 3 (1.8) 9 (3.1) 0.55
Other diseases 12 (7.3) 21 (7.2) 1.00
Quantitative variables expressed as median and standard deviation. Dichotomous
variables expressed in number and (%); Mann–Whitney U or Fisher’s exact
chi-squared test (two-sided), according to the type of variable; Cases, patients with
prevalent or incident coronary heart, cerebrovascular or peripheral artery disease;
Controls, patients without cardiovascular disease.
aThe co-morbidities were standardized according to the Charlson criteria [18].
bHaematological tumors included.
TABLE 2. Distribution of serological IgG phase II titres
against Coxiella burnetii in study patients
Cases
(n = 164)
Controls
(n = 290) p value
<1:256 80 (48.8) 181 (62.4) –
≥1:256 84 (51.2) 109 (37.6) 0.006
≥1:512 22 (13.4) 24 (8.3) 0.10
≥1:1024 9 (5.5) 8 (2.8) 0.10
≥1:2048 6 (3.7) 3 (1.0) 0.07
0.004a
Expressed as (%), and p value obtained by the Fisher’s exact chi-squared test
(two-sided); Cases, patients with prevalent or incident coronary heart, cerebro-
vascular or peripheral artery disease; Controls, patients without cardiovascular
disease.
ap value obtained by Mann–Whitney U for C. burnetii phase II (geometric mean
titre 248.6 (range, 64 to 2048) and 215.5 (range 64 to 2048), respectively).
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although the seroprevalence of the latter was so high that it
invalidated any possible analysis. Although it was not our
intention to build a predictive model of cardiovascular disease,
we observed that the best model achieved for this purpose
only correctly classiﬁed 70% of the patients. This means that
other covariates (not included in the study) could affect the
results through new interactions or by acting as confounding
variables.
Discussion
Original tentative suggestions of a link between Q fever and
cardiovascular disease were in the form of a case report of
acute myocardial infarction in a patient with Q fever infection
[6]. More recently, Ender et al. performed serology on 55
patients subjected to coronary angiography. The geometric
mean titre for C. burnetti phase I was slightly higher in persons
with coronary artery disease than in those without this disease
(p < 0.02) [9]. Further positive relationships were reported in
a follow-up study of people infected during a large outbreak of
Q fever in Switzerland in 1983 [10]. In this study, the patients
who had acute Q fever not only had a higher risk of suffering
from a cerebrovascular accident and ischaemic heart disease
after 12 years, but their mortality was also higher at the end of
this time. However, this study was criticized for not control-
ling for current and past cigarette smoking as a potential
explanation for the excess cardiovascular morbidity and
mortality observed [11]. Later, a nested case-control study
conducted on 335 patients was unable to ﬁnd any relationship
between evidence of past C. burnetti infection and incident
ischaemic disease, despite taking smoking and other potential
confounding factors into account [12]. The inability to ﬁnd a
clear link between these two variables could have been due to
the low seroprevalence of the infection in the populations
studied. As we have shown, the application of speciﬁc
serological markers in populations at high risk of Q fever,
improves the results obtained.
Although previous studies have suggested an association
between smoking status and Q fever, we have observed that
the data existing up to now are contradictory and are unable
to support this hypothesis. In a large outbreak of Q fever
pneumonia in Birmingham, UK, in 1989, 88 (80%) of 110
patients for whom smoking data were available were current
or ex-smokers, and only 22 (20%) had never smoked [19]. A
subsequent case-control study in the same cohort demon-
strated smoking to be a risk factor for Q fever [20]. Smoking
was also shown to be an independent risk factor for Q fever
infection in goat workers in rural Newfoundland [21], in 39
subjects with acute Q fever in southwest England and
Northern Ireland [22], and in 103 patients with recent Q
fever in a rural area of the Netherlands [2]. However, an
extensive study conducted in Northern Ireland did not reach
the same conclusions [23], as in other case-control studies
conducted on subjects with ischaemic heart disease [12]. It
should be noted that smoking appears as a Q fever risk factor
only in studies based on epidemic outbreaks [2, 20–23]. This
may be due to different epidemiological features involved in
each case. Outbreaks occur in very speciﬁc places and at
TABLE 3. Characteristics of patients according to their
Coxiella burnetii serostatus
Seropositives
(n = 193)
Seronegatives
(n = 261) p value
Cardiovascular risk factors
Age 81.2 (7.7) 80.7 (7.6) 0.46
Men 111 (57.5) 132 (45.6) 0.15
Diabetes 62 (32.1) 76 (29.1) 0.53
Hypertension 139 (72.0) 181 (69.3) 0.58
Dyslipidaemia 87 (45.1) 106 (40.6) 0.38
Atrial ﬁbrillationa 89 (46.1) 99 (37.9) 0.08
Smoking 84 (43.5) 94 (36.0) 0.14
Atherosclerotic cardiovascular disease
Coronary heart disease 42 (21.8) 42 (16.1) 0.14
Cerebrovascular disease 42 (21.8) 36 (13.8) 0.03
Peripheral artery disease 23 (11.9) 21 (8.0) 0.20
Other cardiovascular diseases
Cardiac valvulopathies 33 (17.1) 36 (13.8) 0.35
Valvular prosthesis 8 (4.1) 11 (4.2) 1.00
Vascular grafts 7 (3.6) 5 (1.9) 0.40
Other co-morbiditiesb
Congestive heart failure 68 (35.2) 69 (26.4) 0.06
Any tumourc 46 (23.8) 63 (24.1) 1.00
Chronic pulmonary disease 57 (29.5) 65 (24.9) 0.28
Dementia 32 (16.6) 36 (13.8) 0.42
Moderate or severe
renal disease
5 (2.6) 9 (3.4) 0.78
Liver disease 9 (4.6) 7 (2.5) 0.47
Connective tissue disease 3 (1.6) 8 (3.1) 0.38
Quantitative variables expressed as median and standard deviation. Dichotomous
variables expressed in number and (%); Mann–Whitney U or Fisher’s exact
chi-squared test (two-sided), according to the type of variable; Cases, according to
the type of variable.
IgG phase II titres ≥1:256, determined by immunoﬂuorescence assay, were
considered seropositive.
aAtrial ﬁbrillation/atrial ﬂutter (sustained or paroxysmal).
bThe co-morbidities were standardized according to the Charlson criteria [18].
cHaematological tumors included.
TABLE 4. Unadjusted and adjusted relationships between
seropositivity and cardiovascular disease in study patients
Cases
(n = 164)
Controls
(n = 290)
Crude OR Adjusted ORa%
Coxiella burnetti 51.2 37.6 1.7 (1.1–2.5) 2.6 (1.5–4.7)
Chlamydia pneumoniae 83.5 75.4 1.7 (1.0–2.9) 1.5 (0.9–2.6)
CMV 93.3 96.2 0.5 (0.2–1.2) 0.7 (0.3–2.0)
Coxiella burnetti +
Chlamydia
43.3 28.6 1.9 (1.2–2.8) 2.8 (1.5–5.0)
Coxiella burnetti +
Chlamydia + CMV
41.5 26.9 1.9 (2.2–2.8) 2.9 (1.6–5.2)
OR, odds ratio (95% conﬁdence interval); Cases, patients with prevalent or
incident coronary heart, cerebrovascular or peripheral artery disease; Controls,
patients without cardiovascular disease; CMV, Cytomegalovirus.
aAdjusted for sex, hypertension (yes or no), dyslipidaemia (yes or no), smoking
habits (yes or no), diabetes (yes or no), atrial ﬁbrillation (yes or no), and signiﬁcant
interactions between the covariates and the primary endpoint: Coxiella seropos-
itivity with smoking (p = 0.04). Coxiella + Chlamydia seropositivity with smoking
(p = 0.01). Coxiella + Chlamydia + CMV seropositivity with smoking (p = 0.01).
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speciﬁc times, thus the populations involved are more
homogeneous than those included in seroprevalence studies.
We did not ﬁnd a signiﬁcant association between the two
variables in our sample.
We have observed that the majority of the control
variables act as effect-modifying variables, such that the
relationship is greater in their absence. These results are
relevant, and could be linked to the known fact that some
traditional risk factors, such as dyslipidaemia and diabetes, have
a decreasing impact with advancing age [24]. In these
circumstances, other lesser-known risk factors could act.
Infections, for example, are more common in the elderly. This
is due both to deterioration of the immune system associated
with ageing, also called immunosenescence, and the associated
co-morbidities [25]. In this sense, we currently know that
C. burnetti can remain in the body for long periods of time [26],
and be reactivated by immunosuppressive drugs or pregnancy
[27]. As regards this fact, our group has recently demonstrated
that a signiﬁcant proportion of human abortions occurring in
our area could be due to reactivation of Q fever [28].
Something similar could happen in elderly people. The
persistence or reactivation of Q fever, even at a sub-clinical
level, could be establishing a low-grade persistent inﬂamma-
tory process, accelerating the arteriosclerosis process and
precipitating cardiovascular events.
In summary, this study is the ﬁrst to report a link
between serological markers of past Q fever, measured late in
life, and cardiovascular disease. However, it should be investigated
whether this is a cause-effect relationship, or is a relationship
dependent on other variables. This ﬁnding is of potential impor-
tance, because Q fever may be susceptible to prevention [29].
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